deCODE files for bankruptcy

Iceland-based genomics pioneer deCODE linkurl:announced this morning;http://www.decode.com/News/news.php?s=32 (November 17) that it has filed for bankruptcy. It will sell some of its holdings, but plans to continue operating its business and managing its properties as it does now. Image: Wikimedia commons, Jerome Walker, Dennis MytsIn the filing, deCODE listed total assets of $69.9 million and total debt of $313.9 million, as of June 30, 2009. deCODE, launched in 1996, quickly became a leader

Written byJef Akst

| 2 min read

Save for Later

Image: Wikimedia commons,
Jerome Walker, Dennis Myts

In the filing, deCODE listed total assets of $69.9 million and total debt of $313.9 million, as of June 30, 2009. deCODE, launched in 1996, quickly became a leader in human genomics research. In the last two years alone, deCODE scientists have linkurl:published at least 30;http://www.decode.com/Publications/Index.php peer-reviewed research papers, all in top tier journals such as Nature, Science, and the New England Journal of Medicine. But the company has never turned a profit and has lost more than $600 million since its inception. In September, deCODE closed its Woodridge, Illinois facility, cutting about 60 jobs. To address these financial concerns, deCODE "explored multiple restructuring alternatives," said a company press release announcing the bankruptcy filing. As a result, it has initiated the sale of its Iceland-based subsidiary Islensk Erfdagreining (IE) -- which conducts deCODE's human genetics research and manages its personal genetics services -- and its drug discovery and development programs to the US-based Saga Investments LLC. The deal must be approved by the court, but meanwhile, Saga has agreed to give deCODE a loan to support its post-petition operating expenses. The result of this agreement, Wellcome Trust Sanger Institute researcher Daniel MacArthur linkurl:explained in his blog Genetic Future,;http://scienceblogs.com/geneticfuture/2009/11/decode_genetics_finally_goes_u.php is that "pretty much all of the core business that deCODE does will continue, simply under a different name." The concern, however, is that this may only be a "temporary fix," he added. Unless deCODE is able to start generating profit, the company's future is in jeopardy. And as he linkurl:wrote in August,;http://scienceblogs.com/geneticfuture/2009/08/decode_genetics_on_the_brink_o.php "the loss of deCODE would be a genuine and substantial blow to the field of complex trait genetics."
**__Related stories:__***linkurl:deCODE close to broke;http://www.the-scientist.com/blog/display/55884/
[11th August 2009]*linkurl:deCODE falls from NASDAQ grace;http://www.the-scientist.com/blog/display/55200/
[18th November 2008]*linkurl:Trouble for deCODE;http://www.the-scientist.com/blog/display/55089/
[14th October 2008]

Meet the Author

Jef Akst

Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

View Full Profile

deCODE files for bankruptcy

The Scientist ARCHIVES

Become a Member of

Meet the Author

Jef Akst

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies